## Patrizia Mecocci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7530005/publications.pdf

Version: 2024-02-01

4645 2975 35,462 368 93 170 citations h-index g-index papers 391 391 391 40523 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, $18$ , $29$ - $42$ .	0.8	24
2	User experience and acceptance of a device assisting persons with dementia in daily life: a multicenter field study. Aging Clinical and Experimental Research, 2022, 34, 869-879.	2.9	6
3	Usability testing of the first prototype of the MementoÂsystem: a technological device to promote an independent living in people with dementia. Disability and Rehabilitation: Assistive Technology, 2022, , 1-10.	2.2	1
4	Modeling the dynamics of energy imbalance: The free radical theory of aging and frailty revisited. Free Radical Biology and Medicine, 2022, 181, 235-240.	2.9	21
5	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. Alzheimer's and Dementia, 2022, 18, 1957-1968.	0.8	2
6	Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD. Alzheimer's Research and Therapy, 2022, 14, 37.	6.2	12
7	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
8	Al-Based Predictive Modelling of the Onset and Progression of Dementia. Smart Cities, 2022, 5, 700-714.	9.4	2
9	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
10	Uric acid and late-onset Alzheimer's disease: results from the ReGAl 2.0 project. Aging Clinical and Experimental Research, 2021, 33, 361-366.	2.9	17
11	Serum alkaline phosphatase is elevated and inversely correlated with cognitive functions in subjective cognitive decline: results from the ReGAl 2.0 project. Aging Clinical and Experimental Research, 2021, 33, 603-609.	2.9	15
12	The impact of aging in dementia: It is time to refocus attention on the main risk factor of dementia. Ageing Research Reviews, 2021, 65, 101210.	10.9	15
13	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
14	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	7.9	30
15	Senotherapeutics: Targeting senescent cells for the main age-related diseases. Mechanisms of Ageing and Development, 2021, 197, 111526.	4.6	29
16	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.8	174
17	Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 20.	6.2	60
18	Editorial for the Special Issue "Molecular Bases of Senescence― International Journal of Molecular Sciences, 2021, 22, 11873.	4.1	0

#	Article	IF	CITATIONS
19	Prevention of Age-Related Cognitive Impairment, Alzheimer's Disease, and Dementia. , 2021, , 3948-3956.		O
20	A stepwise approach towards diagnostic workup in dementia using online cognitive tools. Alzheimer's and Dementia, $2021,17,.$	0.8	0
21	The "Artwork Effect―paradigm: A model for planning and assessing cognitive stimulation for people with dementia through museum visits. Dementia, 2020, 19, 2867-2875.	2.0	2
22	Telomeres Increasingly Develop Aberrant Structures in Aging Humans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 230-235.	3.6	10
23	Vitamin E and Alzheimer's disease: the mediating role of cellular aging. Aging Clinical and Experimental Research, 2020, 32, 459-464.	2.9	26
24	Glutathione Serum Levels and Rate of Multimorbidity Development in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1089-1094.	3.6	20
25	Lower serum levels of IL-13 is associated with increased carotid intima-media thickness in old age subjects. Aging Clinical and Experimental Research, 2020, 32, 1289-1294.	2.9	4
26	Beta-carotene, telomerase activity and Alzheimer's disease in old age subjects. European Journal of Nutrition, 2020, 59, 119-126.	3.9	34
27	Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia. Journal of the American Medical Directors Association, 2020, 21, 486-492.e7.	2.5	11
28	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, $11$ , $4016$ .	12.8	26
29	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	3.1	51
30	cCOG: A webâ€based cognitive test tool for detecting neurodegenerative disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12083.	2.4	9
31	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
32	MicroRNAs Modulate the Pathogenesis of Alzheimer's Disease: An In Silico Analysis in the Human Brain. Genes, 2020, 11, 983.	2.4	14
33	Medico-legal assessment of personal damage in older people: report from a multidisciplinary consensus conference. International Journal of Legal Medicine, 2020, 134, 2319-2334.	2.2	7
34	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808.	0.8	1
35	Differential diagnosis of dementia combining webâ <b>€b</b> ased cognitive testing and MRI. Alzheimer's and Dementia, 2020, 16, e042626.	0.8	0
36	Plasmaâ€based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046490.	0.8	0

3

#	Article	IF	Citations
37	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745.	3.3	30
38	COVID-19: A Geriatric Emergency. Geriatrics (Switzerland), 2020, 5, 24.	1.7	30
39	Evaluating 2-[18F]FDG-PET in differential diagnosis of dementia using a data-driven decision model. Neurolmage: Clinical, 2020, 27, 102267.	2.7	9
40	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. Medical Image Analysis, 2020, 66, 101714.	11.6	90
41	Association of Peripheral Insulin Resistance and Other Markers of Type 2 Diabetes Mellitus with Brain Amyloid Deposition in Healthy Individuals at Risk of Dementia. Journal of Alzheimer's Disease, 2020, 76, 1243-1248.	2.6	17
42	The Importance of Cellular Senescence in Frailty and Cardiovascular Diseases. Advances in Experimental Medicine and Biology, 2020, 1216, 79-86.	1.6	11
43	Cholinesterase inhibitors in dementias. , 2020, , 457-475.		1
44	Prevention of Age-Related Cognitive Impairment, Alzheimer's Disease, and Dementia. , 2020, , 1-9.		0
45	Italian version and normative data of Addenbrooke's Cognitive Examination III. International Psychogeriatrics, 2019, 31, 241-249.	1.0	7
46	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	2.2	2
47	Diabetes drugs in the fight against Alzheimer's disease. Ageing Research Reviews, 2019, 54, 100936.	10.9	91
48	Cognitive Decline and Alzheimer's Disease in Old Age: A Sex-Specific Cytokinome Signature. Journal of Alzheimer's Disease, 2019, 72, 911-918.	2.6	13
49	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
50	Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nature Neuroscience, 2019, 22, 1617-1623.	14.8	358
51	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease. Translational Psychiatry, 2019, 9, 55.	4.8	32
52	The orthogeriatric comanagement improves clinical outcomes of hip fracture in older adults. Osteoporosis International, 2019, 30, 907-916.	3.1	83
53	Validation study of the Italian version of Communication Activities of the Daily Living (CADL 2) as an ecologic cognitive assessment measure in older subjects. Neurological Sciences, 2019, 40, 2081-2088.	1.9	4
54	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). Neurolmage: Clinical, 2019, 23, 101846.	2.7	18

#	Article	IF	CITATIONS
55	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
56	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimer's Research and Therapy, 2019, 11, 25.	6.2	23
57	DPP-4 inhibitors: meeting the needs of the very old population. Acta Diabetologica, 2019, 56, 819-819.	2.5	1
58	Cachexia and advanced dementia. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 263-277.	7.3	31
59	Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology, 2019, 29, 4937-4947.	4.5	23
60	Detecting frontotemporal dementia syndromes using MRI biomarkers. NeuroImage: Clinical, 2019, 22, 101711.	2.7	35
61	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 2019, 16, 91-101.	1.4	23
62	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	2.6	14
63	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
64	Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial. Nutrients, 2019, 11, 2778.	4.1	16
65	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
66	Hypovitaminosis D: A Disease Marker in Hospitalized Very Old Persons at Risk of Malnutrition. Nutrients, 2019, 11, 128.	4.1	14
67	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 4333-4344.	4.0	19
68	Automatic MRI Quantifying Methods in Behavioral-Variant Frontotemporal Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 51-59.	1.3	19
69	Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2018, 65, 98-108.	3.1	110
70	A Long Journey into Aging, Brain Aging, and Alzheimer's Disease Following the Oxidative Stress Tracks. Journal of Alzheimer's Disease, 2018, 62, 1319-1335.	2.6	181
71	Brain Aging and Late-Onset Alzheimer's Disease: A Matter of Increased Amyloid or Reduced Energy?. Journal of Alzheimer's Disease, 2018, 64, S397-S404.	2.6	17
72	Telomerase activation and human health-span: an open issue. Aging Clinical and Experimental Research, 2018, 30, 221-223.	2.9	3

#	Article	IF	CITATIONS
73	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2018, 14, 280-292.	0.8	246
74	Is the 15-item Geriatric Depression Scale a Fair Screening Tool? A Differential Item Functioning Analysis Across Gender and Age. Psychological Reports, 2018, 121, 1167-1182.	1.7	12
75	Does the 15-item Geriatric Depression Scale function differently in old people with different levels of cognitive functioning?. Journal of Affective Disorders, 2018, 227, 471-476.	4.1	20
76	P1â€328: CONSISTENCY OF MUISTIKKO WEBâ€BASED COGNITIVE TEST WHILE PERFORMED AT CLINIC AND AT HOME. Alzheimer's and Dementia, 2018, 14, P418.	0.8	0
77	P2â€350: DETECTING FRONTOTEMPORAL DEMENTIA USING A NOVEL MRI IMAGING BIOMARKER: THE ANTERIOR VERSUS POSTERIOR INDEX. Alzheimer's and Dementia, 2018, 14, P821.	0.8	0
78	P2â€349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. Alzheimer's and Dementia, 2018, 14, P820.	0.8	0
79	Mining clinical and laboratory data of neurodegenerative diseases by Machine Learning: transcriptomic biomarkers. , 2018, , .		2
80	Telomere Targeting. , 2018, , .		0
81	Polypharmacy in older people: lessons from 10Âyears of experience with the REPOSIÂregister. Internal and Emergency Medicine, 2018, 13, 1191-1200.	2.0	45
82	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	3.4	29
83	Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 509-518.	2.4	19
84	Stability of graph theoretical measures in structural brain networks in Alzheimer's disease. Scientific Reports, 2018, 8, 11592.	3.3	41
85	Effect of Mediterranean Diet on Healthy Brain Aging. , 2018, , 89-101.		1
86	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 439.	3.4	21
87	Cognitive Decline. Practical Issues in Geriatrics, 2018, , 67-80.	0.8	2
88	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
89	Mitochondrial genes are altered in blood early in Alzheimer's disease. Neurobiology of Aging, 2017, 53, 36-47.	3.1	132
90	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	1.9	20

#	Article	IF	CITATIONS
91	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.8	33
92	Biomarkers for Early Diagnosis ofÂAlzheimer's Disease in the Oldest Old: Yes or No?. Journal of Alzheimer's Disease, 2017, 58, 323-335.	2.6	11
93	Clinical Features Associated with Delirium Motor Subtypes in Older Inpatients: Results of a Multicenter Study. American Journal of Geriatric Psychiatry, 2017, 25, 1064-1071.	1.2	38
94	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. Neurolmage: Clinical, 2017, 15, 613-624.	2.7	38
95	Anticholinergic burden and functional status in older people with cognitive impairment: Results from the ReGAl project. Journal of Nutrition, Health and Aging, 2017, 21, 389-396.	3.3	21
96	The local reliability of the 15-item version of the Geriatric Depression Scale: An item response theory (IRT) study. Journal of Psychosomatic Research, 2017, 96, 84-88.	2.6	18
97	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	2.6	72
98	Short-Term Response is not Predictive ofÂLong-Term Response toÂAcetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer's Disease: A"Real World―Study. Journal of Alzheimer's Disease, 2017, 56, 239-248.	2.6	11
99	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.8	143
100	No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 85-99.	2.6	10
101	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
102	Early post-surgical cognitive dysfunction is a risk factor for mortality among hip fracture hospitalized older persons. Osteoporosis International, 2017, 28, 667-675.	3.1	37
103	Association of blood lipids with Alzheimer's disease: AÂcomprehensiveÂlipidomics analysis. Alzheimer's and Dementia, 2017, 13, 140-151.	0.8	144
104	[P1–009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P234.	′: <sub>0.8</sub>	0
105	[P1–326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P380.	0.8	O
106	[P1–375]: DATAâ€DRIVEN DIAGNOSIS OF DEMENTIA DISORDERS: THE PREDICTND VALIDATION STUDY. Alzheimer's and Dementia, 2017, 13, P405.	0.8	2
107	[O4–03–06]: SHORTâ€₹ERM RESPONSE IS NOT PREDICTIVE OF LONGâ€₹ERM RESPONSE TO ACETYLCHOLINESTERASE INHIBITORS IN OLD AGE SUBJECTS WITH ALZHEIMER's DISEASE: A â€~REAL WORLD' STUDY. Alzheimer's and Dementia, 2017, 13, P1234.	<sup>M</sup> O.8	O
108	Of Energy and Entropy: The Ineluctable Impact of Aging in Old Age Dementia. International Journal of Molecular Sciences, 2017, 18, 2672.	4.1	28

#	Article	IF	CITATIONS
109	A Multi-Cohort Study of ApoE É>4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 1159-1174.	2.6	36
110	Prevalence and Correlates of Behavioral Disorders in Old Age Subjects with Cognitive Impairment: Results from the ReGAl Project. Journal of Alzheimer's Disease, 2017, 60, 1275-1283.	2.6	17
111	Advanced Research in Telomeres and Disease Risk. , 2017, , 149-161.		0
112	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1105-1114.	2.6	30
113	Nutrition and lifestyle in healthy aging: the telomerase challenge. Aging, 2016, 8, 12-15.	3.1	46
114	Fatigue as a clinical sign of biological aging: exploratory analyses from the <scp>MINDED</scp> project. Geriatrics and Gerontology International, 2016, 16, 533-534.	1.5	8
115	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. Brain Topography, 2016, 29, 296-307.	1.8	44
116	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	2.7	137
117	Vitamin E family: Role in the pathogenesis and treatment of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 182-191.	3.7	49
118	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
119	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
120	A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort. Journal of Alzheimer's Disease, 2016, 53, 981-989.	2.6	22
121	"Delirium Day― a nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool. BMC Medicine, 2016, 14, 106.	5.5	204
122	Subjective memory complaints and depression as clinical symptoms of disseminated nocardiosis by <i>Nocardia abscessus</i> . Geriatrics and Gerontology International, 2016, 16, 1167-1168.	1.5	2
123	"Oldest old―man with odynophagia and generalized asthenia: It could be tetanus!. Geriatrics and Gerontology International, 2016, 16, 885-887.	1.5	0
124	Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease. Cerebral Cortex, 2016, 26, 3476-3493.	2.9	110
125	Physical activity and inflammation: effects on grayâ€matter volume and cognitive decline in aging. Human Brain Mapping, 2016, 37, 3462-3473.	3.6	48
126	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. European Radiology, 2016, 26, 2597-2610.	4.5	39

#	Article	IF	Citations
127	Healthy brain ageing and cognition: Nutritional factors. European Geriatric Medicine, 2016, 7, 77-85.	2.8	22
128	Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations. Neurodegenerative Diseases, 2016, 16, 77-86.	1.4	29
129	The clock drawing test as a screening tool in mild cognitive impairment and very mild dementia: a new brief method of scoring and normative data in the elderly. Neurological Sciences, 2016, 37, 867-873.	1.9	35
130	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	3.1	115
131	Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nature Neuroscience, 2016, 19, 420-431.	14.8	204
132	Lack of Energy and Negative Health-Related Outcomes in Nursing Home Residents: Results From the INCUR Study. Journal of the American Medical Directors Association, 2016, 17, 525-529.	2.5	5
133	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 79-92.	2.6	31
134	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	2.6	2
135	Lymphocytic Mitochondrial Aconitase Activity is Reduced in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 44, 649-660.	2.6	42
136	Practical cutâ€offs for visual rating scales of medial temporal, frontal and posterior atrophy in <scp>A</scp> lzheimer's disease and mild cognitive impairment. Journal of Internal Medicine, 2015, 278, 277-290.	6.0	91
137	Fracture prevention service to bridge the osteoporosis care gap. Clinical Interventions in Aging, 2015, 10, 1035.	2.9	35
138	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. Journal of Alzheimer's Disease, 2015, 49, 659-669.	2.6	43
139	Circulating Proteomic Signatures of Chronological Age. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 809-816.	3.6	106
140	Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology, 2015, 77, 547-552.	5.3	48
141	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. Journal of Alzheimer's Disease, 2015, 45, 851-864.	2.6	10
142	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
143	Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Translational Psychiatry, 2015, 5, e494-e494.	4.8	105
144	Association of increased carotid intima–media thickness and lower plasma levels of vitamin C and vitamin E in old age subjects: implications for Alzheimer's disease. Journal of Neural Transmission, 2015, 122, 523-530.	2.8	15

#	Article	IF	CITATIONS
145	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
146	Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Translational Psychiatry, 2015, 5, e584-e584.	4.8	39
147	Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease in Two Independent Cohorts. Brain Topography, 2015, 28, 746-759.	1.8	69
148	From cellular senescence to Alzheimer's disease: The role of telomere shortening. Ageing Research Reviews, 2015, 22, 1-8.	10.9	99
149	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer's Research and Therapy, 2015, 7, 17.	6.2	419
150	Normative data for the ACE-R in an Italian population sample. Neurological Sciences, 2015, 36, 2185-2190.	1.9	13
151	Fatigue: Relevance and implications in the aging population. Experimental Gerontology, 2015, 70, 78-83.	2.8	73
152	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
153	FASTKD2 is associated with memory and hippocampal structure in older adults. Molecular Psychiatry, 2015, 20, 1197-1204.	7.9	33
154	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
155	Predicting Progression of Alzheimer's Disease Using Ordinal Regression. PLoS ONE, 2014, 9, e105542.	2.5	44
156	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. Frontiers in Aging Neuroscience, 2014, 6, 145.	3.4	29
157	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. NeuroImage: Clinical, 2014, 6, 115-125.	2.7	233
158	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	8.4	75
159	Nutraceuticals in cognitive impairment and Alzheimer $ ilde{A}$ ¢ $\hat{a}$ , $\neg \hat{a}$ ,,¢s disease. Frontiers in Pharmacology, 2014, 5, 147.	3.5	99
160	Influence of age, disease onset and <i>ApoE4</i> on visual medial temporal lobe atrophy cutâ€offs. Journal of Internal Medicine, 2014, 275, 317-330.	6.0	60
161	Clinical trials and lateâ€stage drug development for <scp>A</scp> lzheimer's disease: an appraisal from 1984 to 2014. Journal of Internal Medicine, 2014, 275, 251-283.	6.0	540
162	Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 271-278.	3.1	256

#	Article	IF	Citations
163	Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 764-775.	6.4	30
164	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	3.1	9
165	Influence of +1245 A/G MT1A polymorphism on advanced glycation end-products (AGEs) in elderly: effect of zinc supplementation. Genes and Nutrition, 2014, 9, 426.	2.5	16
166	Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's and Dementia, 2014, 10, 799.	0.8	180
167	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.8	182
168	Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiology of Aging, 2014, 35, 279-290.	3.1	56
169	CERAD Neuropsychological Compound Scores are Accurate in Detecting Prodromal Alzheimer's Disease: A Prospective AddNeuroMed Study. Journal of Alzheimer's Disease, 2014, 39, 679-690.	2.6	35
170	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
171	Interaction Between Bone and Muscle in Older Persons with Mobility Limitations. Current Pharmaceutical Design, 2014, 20, 3178-3197.	1.9	88
172	Body mass index, lifestyles, physical performance and cognitive decline: The "Treviso Longeva (Trelong)―study. Journal of Nutrition, Health and Aging, 2013, 17, 378-384.	3.3	57
173	Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Experimental Gerontology, 2013, 48, 1428-1435.	2.8	99
174	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
175	Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radical Biology and Medicine, 2013, 65, 595-606.	2.9	56
176	Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study. Journal of Alzheimer's Disease, 2013, 38, 515-531.	2.6	160
177	Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Research - Neuroimaging, 2013, 212, 89-98.	1.8	98
178	Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Molecular Psychiatry, 2013, 18, 781-787.	7.9	81
179	An MRIâ€based index to measure the severity of Alzheimer's diseaseâ€like structural pattern in subjects with mild cognitive impairment. Journal of Internal Medicine, 2013, 273, 396-409.	6.0	53
180	Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics. Molecular Psychiatry, 2013, 18, 739-739.	7.9	8

#	Article	IF	Citations
181	Classification and prediction of clinical diagnosis of Alzheimer's disease based on <scp>MRI</scp> and plasma measures of αâ€ſĴ3â€tocotrienols and Ĵ3â€tocopherol. Journal of Internal Medicine, 2013, 273, 602-621.	6.0	67
182	A Blood Gene Expression Marker of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 737-753.	2.6	91
183	Entorhinal Cortex Thickness Predicts Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 755-766.	2.6	105
184	CERAD Neuropsychological Total Scores Reflect Cortical Thinning in Prodromal Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 446-458.	1.3	7
185	Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 223-232.	0.4	2
186	Classification Models for Alzheimer's Disease Detection. Communications in Computer and Information Science, 2013, , 193-202.	0.5	9
187	Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer's Disease. PLoS ONE, 2013, 8, e64971.	2.5	122
188	Plasma Levels of Complement 4a Protein are Increased in Alzheimer's Disease. Alzheimer Disease and Associated Disorders, 2012, 26, 329-334.	1.3	33
189	Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood. Journal of Alzheimer's Disease, 2012, 30, 685-710.	2.6	141
190	HO-1/BVR-A System Analysis in Plasma from Probable Alzheimer's Disease and Mild Cognitive Impairment Subjects: A Potential Biochemical Marker for the Prediction of the Disease. Journal of Alzheimer's Disease, 2012, 32, 277-289.	2.6	43
191	Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer's disease. International Psychogeriatrics, 2012, 24, 99-107.	1.0	36
192	Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radical Biology and Medicine, 2012, 53, 1868-1876.	2.9	59
193	An ontology-based personalization of health-care knowledge to support clinical decisions for chronically ill patients. Journal of Biomedical Informatics, 2012, 45, 429-446.	4.3	170
194	Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiology of Aging, 2012, 33, 1843.e9-1843.e17.	3.1	24
195	Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiology of Aging, 2012, 33, 2282-2290.	3.1	134
196	Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 631-638.	3.8	217
197	Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. Journal of Translational Medicine, 2012, 10, 217.	4.4	26
198	A Review of the Major Vascular Risk Factors Related to Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 521-530.	2.6	77

#	Article	IF	CITATIONS
199	Education increases reserve against Alzheimer's diseaseâ€"evidence from structural MRI analysis. Neuroradiology, 2012, 54, 929-938.	2.2	148
200	Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS ONE, 2012, 7, e44260.	2.5	89
201	Identification of <i>cis-</i> regulatory variation influencing protein abundance levels in human plasma. Human Molecular Genetics, 2012, 21, 3719-3726.	2.9	94
202	Fetal variant of circle of the Willis and bilateral symmetrical parietal stroke. Neurological Sciences, 2012, 33, 309-311.	1.9	3
203	THE TREVISO DEMENTIA (TREDEM) STUDY: A BIOMEDICAL, NEURORADIOLOGICAL, NEUROPSYCHOLOGICAL AND SOCIAL INVESTIGATION OF DEMENTIA IN NORTH-EASTERN ITALY. Journal of Frailty & Demention (1997), 1, 1-7.	1.3	11
204	CERAD Neuropsychological Battery Total Score in Multinational Mild Cognitive Impairment and Control Populations: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2011, 22, 1089-1097.	2.6	40
205	Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. NeuroImage, 2011, 56, 212-219.	4.2	190
206	AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neurolmage, 2011, 58, 818-828.	4.2	121
207	Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neurolmage, 2011, 54, 1178-1187.	4.2	128
208	Increased Protein and Lipid Oxidative Damage in Mitochondria Isolated from Lymphocytes from Patients with Alzheimer's Disease: Insights into the Role of Oxidative Stress in Alzheimer's Disease and Initial Investigations into a Potential Biomarker for this Dementing Disorder. Journal of Alzheimer's Disease, 2011, 24, 77-84.	2.6	100
209	Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groupsâ€"The AddNeuroMed study. Neurobiology of Aging, 2011, 32, 1198-1206.	3.1	69
210	Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. International Journal of Alzheimer's Disease, 2011, 2011, 1-14.	2.0	18
211	Combinatorial Markers of Mild Cognitive Impairment Conversion to Alzheimer's Disease - Cytokines and MRI Measures Together Predict Disease Progression. Journal of Alzheimer's Disease, 2011, 26, 395-405.	2.6	47
212	Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimer's Disease. PLoS ONE, 2011, 6, e22506.	2.5	103
213	Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. PLoS ONE, 2011, 6, e28527.	2.5	106
214	Lysosomal $\hat{l}^2$ -Galactosidase and $\hat{l}^2$ -Hexosaminidase Activities Correlate with Clinical Stages of Dementia Associated with Alzheimer's Disease and Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease, 2011, 24, 785-797.	2.6	35
215	Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenetics and Genomics, 2011, 21, 225-230.	1.5	62
216	Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Molecular Psychiatry, 2011, 16, 1130-1138.	7.9	133

#	Article	IF	Citations
217	The AddNeuroMed framework for multiâ€entre MRI assessment of Alzheimer's disease : experience from the first 24 months. International Journal of Geriatric Psychiatry, 2011, 26, 75-82.	2.7	127
218	Apathy and cortical atrophy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2011, 26, 741-748.	2.7	84
219	Validation Study of the Italian Addenbrooke's Cognitive Examination Revised in a Young-Old and Old-Old Population. Dementia and Geriatric Cognitive Disorders, 2011, 32, 301-307.	1.5	48
220	Deep Sequencing of the Nicastrin Gene in Pooled DNA, the Identification of Genetic Variants That Affect Risk of Alzheimer's Disease. PLoS ONE, 2011, 6, e17298.	2.5	21
221	Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. Clinical Laboratory, 2011, 57, 887-93.	0.5	13
222	Association of MT1A haplotype with cardiovascular disease and antioxidant enzyme defense in elderly Greek population: comparison with an Italian cohort. Journal of Nutritional Biochemistry, 2010, 21, 1008-1014.	4.2	21
223	Alzheimer's disease: clinical trials and drug development. Lancet Neurology, The, 2010, 9, 702-716.	10.2	1,033
224	Blood homocysteine and risk of depression in the elderly. Archives of Gerontology and Geriatrics, 2010, 51, 21-25.	3.0	31
225	Decreased dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) concentrations in plasma of Alzheimer's disease (AD) patients. Archives of Gerontology and Geriatrics, 2010, 51, e16-e18.	3.0	55
226	Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clinical Biochemistry, 2010, 43, 267-271.	1.9	35
227	Metabolic Syndrome and Risk of Dementia in Older Adults. Journal of the American Geriatrics Society, 2010, 58, 487-492.	2.6	86
228	Effect of APOE $\hat{l}\mu 4$ Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2010, 21, 947-966.	2.6	82
229	Emotional and Psychological Distress of Persons Involved in the Care of Patients with Alzheimer Disease Predicts Falls and Fractures in Their Care Recipients. Dementia and Geriatric Cognitive Disorders, 2010, 30, 33-38.	1.5	18
230	Cognitive Performance in Elderly Patients Undergoing Carotid Endarterectomy or Carotid Artery Stenting: A Twelve-Month Follow-Up Study. Cerebrovascular Diseases, 2010, 30, 244-251.	1.7	47
231	APOE & Thicknesses and Volumes. Dementia and Geriatric Cognitive Disorders, 2010, 30, 229-237.	1.5	40
232	High Plasma Levels of Vitamin E Forms and Reduced Alzheimer's Disease Risk in Advanced Age. Journal of Alzheimer's Disease, 2010, 20, 1029-1037.	2.6	144
233	Insight, cognition and quality of life in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 331-336.	1.9	77
234	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	12.3	353

#	Article	IF	Citations
235	Introduction. Disease-a-Month, 2010, 56, 105.	1.1	1
236	Hypertension and Cognitive Function in the Elderly. Disease-a-Month, 2010, 56, 106-147.	1.1	35
237	Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2010, 31, 1375-1385.	3.1	104
238	Prevalence of Aging-Associated Cognitive Decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on Epidemiology of Alzheimer's disease (IPREA). Aging Clinical and Experimental Research, 2010, 22, 440-449.	2.9	22
239	Psychotic Symptoms in Alzheimer's Disease and 5-HTTLPR Polymorphism of the Serotonin Transporter Gene: Evidence for an Association. Journal of Alzheimer's Disease, 2009, 16, 173-180.	2.6	18
240	Effect of a <i>CYP2D6</i> polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology, 2009, 73, 761-767.	1.1	102
241	Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: postâ€hoc analyses of ADASâ€cog and SIB total and singleâ€item scores from six randomized, doubleâ€blind, placeboâ€controlled studies. International Journal of Geriatric Psychiatry, 2009, 24, 532-538.	2.7	65
242	MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. Annals of the New York Academy of Sciences, 2009, 1180, 47-55.	3.8	121
243	AddNeuroMedâ€"The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 36-46.	3 <b>.</b> 8	193
244	Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Research Reviews, 2009, 8, 285-305.	10.9	211
245	High Fruit and Vegetable Intake is Positively Correlated with Antioxidant Status and Cognitive Performance in Healthy Subjects. Journal of Alzheimer's Disease, 2009, 17, 921-927.	2.6	122
246	Influence of comorbidity and cognitive status on instrumental activities of daily living in amnestic mild cognitive impairment: results from the ReGAl project. International Journal of Geriatric Psychiatry, 2008, 23, 523-530.	2.7	92
247	Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types. Acta Psychiatrica Scandinavica, 2008, 117, 455-464.	4.5	75
248	Mild Cognitive Impairment: Epidemiology and Dementia Risk in an Elderly Italian Population. Journal of the American Geriatrics Society, 2008, 56, 51-58.	2.6	138
249	Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects. Experimental Gerontology, 2008, 43, 445-451.	2.8	77
250	Zinc, Metallothioneins, Longevity: Effect of Zinc Supplementation on Antioxidant Response: A Zincage Study. Rejuvenation Research, 2008, 11, 419-423.	1.8	9
251	Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium. Dementia and Geriatric Cognitive Disorders, 2008, 25, 1-8.	1.5	167
252	Functional Disability in Early Alzheimer's Disease – A Validation Study of the Italian Version of the Disability Assessment for Dementia Scale. Dementia and Geriatric Cognitive Disorders, 2008, 25, 186-194.	1.5	24

#	Article	IF	Citations
253	Antioxidant Agents in Alzheimers Disease. Central Nervous System Agents in Medicinal Chemistry, 2008, 8, 48-63.	1.1	10
254	Pooled Analyses on Cognitive Effects of Memantine in Patients with Moderate to Severe Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 193-199.	2.6	50
255	Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. American Journal of Clinical Nutrition, 2008, 87, 1306-1313.	4.7	54
256	Visuospatial Planning and Problem Solving in Alzheimer's Disease Patients: A Study with the Tower of London Test. Dementia and Geriatric Cognitive Disorders, 2007, 24, 424-428.	1.5	31
257	Vascular Risk Factors in Mild Cognitive Impairment Subtypes. Dementia and Geriatric Cognitive Disorders, 2007, 24, 448-456.	1.5	31
258	Neuropsychiatric Syndromes in Dementia. Dementia and Geriatric Cognitive Disorders, 2007, 24, 457-463.	1.5	305
259	Mild Cognitive Impairment: A Systematic Review. Journal of Alzheimer's Disease, 2007, 12, 23-35.	2.6	202
260	Hypertension and Cognitive Function in the Elderly. American Journal of Therapeutics, 2007, 14, 533-554.	0.9	34
261	Elevated Lipid Peroxidation Biomarkers and Low Antioxidant Status in Atherosclerotic Patients with Increased Carotid or Iliofemoral Intima Media Thickness. Journal of Investigative Medicine, 2007, 55, 163-167.	1.6	38
262	Vitamin E Biotransformation in Humans. Vitamins and Hormones, 2007, 76, 263-280.	1.7	38
263	The Multifaceted Aspects of Alzheimer's Disease: From Social to Molecular Problems. Journal of Alzheimer's Disease, 2007, 12, 1-1.	2.6	3
264	Different antioxidant profiles in Italian centenarians: the Sardinian peculiarity. European Journal of Clinical Nutrition, 2007, 61, 922-924.	2.9	21
265	Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease. Amino Acids, 2007, 32, 553-559.	2.7	<b>7</b> 5
266	Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. Journal of the Neurological Sciences, 2006, 247, 187-191.	0.6	29
267	Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiology of Aging, 2006, 27, 926-932.	3.1	101
268	Association between apolipoprotein E e4 allele and apathy in probable Alzheimer's disease Acta Psychiatrica Scandinavica, 2006, 113, 59-63.	4.5	33
269	Antioxidant enzyme activities in healthy old subjects: influence of age, gender and zinc status. Biogerontology, 2006, 7, 391-398.	3.9	43
270	Congestive heart failure and Alzheimer's disease. Neurological Research, 2006, 28, 588-594.	1.3	32

#	Article	IF	Citations
271	Dietary habits are major determinants of the plasma antioxidant status in healthy elderly subjects. British Journal of Nutrition, 2005, 94, 639-642.	2.3	67
272	Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 827, 65-75.	2.3	556
273	Effects of vitamin C and aspirin in ischemic strokeâ€related lipid peroxidation: Results of the AVASAS (Aspirin Versus Ascorbic acid plus Aspirin in Stroke) Study. BioFactors, 2005, 24, 265-274.	5.4	23
274	Potential markers of oxidative stress in stroke. Free Radical Biology and Medicine, 2005, 39, 841-852.	2.9	354
275	Predictors of high level of burden and distress in caregivers of demented patients: results of an Italian multicenter study. International Journal of Geriatric Psychiatry, 2005, 20, 168-174.	2.7	151
276	Elderly Patients With Cognitive Impairment Have a High Risk for Functional Decline During Hospitalization: The GIFA Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1576-1580.	3.6	119
277	Cognitive Impairment Is the Major Risk Factor for Development of Geriatric Syndromes during Hospitalization: Results from the GIFA Study. Dementia and Geriatric Cognitive Disorders, 2005, 20, 262-269.	1.5	94
278	Development of a Short Form of the Severe Impairment Battery. American Journal of Geriatric Psychiatry, 2005, 13, 999-1005.	1.2	48
279	Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiology of Aging, 2005, 26, 987-994.	3.1	84
280	Management of Glaucoma: Focus on Pharmacological Therapy. Drugs and Aging, 2005, 22, 1-21.	2.7	166
281	The Caregiver Burden Inventory in evaluating the burden of caregivers of elderly demented patients: results from a multicenter study. Aging Clinical and Experimental Research, 2005, 17, 46-53.	2.9	110
282	Development of a Short Form of the Severe Impairment Battery. American Journal of Geriatric Psychiatry, 2005, 13, 999-1005.	1.2	38
283	Plasma Antioxidant Status, Immunoglobulin G Oxidation and Lipid Peroxidation in Demented Patients: Relevance to Alzheimer Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 18, 265-270.	1.5	110
284	Rapidly Progressive Aphasic Dementia with Motor Neuron Disease: A Distinctive Clinical Entity. Dementia and Geriatric Cognitive Disorders, 2004, 17, 21-28.	1.5	30
285	Antioxidants for the treatment of mild cognitive impairment. Neurological Research, 2004, 26, 598-602.	1.3	47
286	Oxidative stress in Alzheimer's disease: a selective status report. Neuroscience Research Communications, 2004, 35, 202-212.	0.2	2
287	P4-235 Protein oxidation, lipid peroxidation and antioxidant status are similarly altered in Alzheimer disease and vascular dementia. Neurobiology of Aging, 2004, 25, S542.	3.1	1
288	Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. Journal of Cardiac Failure, 2004, 10, 334-338.	1.7	86

#	Article	IF	Citations
289	Depression in the elderly: new concepts and therapeutic approaches. Aging Clinical and Experimental Research, 2004, 16, 176-189.	2.9	31
290	P3-114 Comorbidity and polipharmacotherapy in dementia: the regal project in Italy. Neurobiology of Aging, 2004, 25, S387.	3.1	0
291	Short-term and long-term vitamin C supplementation in humans dose-dependently increases the resistance of plasma to ex vivo lipid peroxidation. Archives of Biochemistry and Biophysics, 2004, 423, 109-115.	3.0	63
292	O1-06-01 Cognitive impairment is the major risk factor of adverse events in hospitalised elderly patients. Neurobiology of Aging, 2004, 25, S21.	3.1	0
293	P1-019 Behavioral and psychological symptoms in dementia: a population-based study. Neurobiology of Aging, 2004, 25, S99.	3.1	1
294	P2-175 Role of proton magnetic resonance spectroscopy (1H-MRS) in predicting the conversion of mild cognitive impairment to dementia. Neurobiology of Aging, 2004, 25, S276-S277.	3.1	0
295	Oxidative stress in mild cognitive impairment and Alzheimer disease: A continuum. Journal of Alzheimer's Disease, 2004, 6, 159-163.	2.6	64
296	Cognitive impairment: a key feature of congestive heart failure in the elderly. Journal of Neurology, 2003, 250, 1456-1463.	3.6	149
297	Axonal injury within language network in primary progressive aphasia. Annals of Neurology, 2003, 53, 242-247.	5.3	53
298	Validation of the Five-Item Geriatric Depression Scale in Elderly Subjects in Three Different Settings. Journal of the American Geriatrics Society, 2003, 51, 694-698.	2.6	334
299	Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 915-919.	3.1	530
300	Cigarette smoking cessation increases plasma levels of several antioxidant micronutrients and improves resistance towards oxidative challenge. British Journal of Nutrition, 2003, 90, 147-150.	2.3	98
301	Marked Decrease in Plasma Antioxidants in Aged Osteoporotic Women: Results of a Cross-Sectional Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1523-1527.	3.6	472
302	Cathepsin D Polymorphism in Italian Elderly Subjects with Sporadic Late-Onset Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2003, 16, 151-155.	1.5	13
303	Genetic Factors Associated With the Absence of Atherosclerosis in Octogenarians. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M611-M615.	3.6	15
304	Lymphocyte Oxidative DNA Damage and Plasma Antioxidants in Alzheimer Disease. Archives of Neurology, 2002, 59, 794.	4.5	212
305	Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. Journal of Alzheimer's Disease, 2002, 4, 517-522.	2.6	115
306	MEMORY ABILITIES IN HEALTHY ELDERLY SUBJECTS: A FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY. , 2002, , .		0

#	Article	IF	Citations
307	Plasma Carotenoid and Malondialdehyde Levels in Ischemic Stroke Patients: Relationship to Early Outcome. Free Radical Research, 2002, 36, 265-268.	3.3	99
308	Effects of vitamin A administration on serum thyrotropin concentrations in healthy human subjects. Metabolism: Clinical and Experimental, 2002, 51, 691-694.	3.4	8
309	Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. Free Radical Biology and Medicine, 2002, 32, 148-152.	2.9	90
310	Proton Magnetic Resonance Spectroscopy Reveals Similar White Matter Biochemical Changes in Patients with Chronic Hypertension and Early Alzheimer's Disease. Journal of the American Geriatrics Society, 2002, 50, 1707-1710.	2.6	34
311	Use of Artificial Networks in Clinical Trials: A Pilot Study to Predict Responsiveness to Donepezil in Alzheimer's Disease. Journal of the American Geriatrics Society, 2002, 50, 1857-1860.	2.6	24
312	Arginine vasopressin in the cytoplasm and nuclear fraction of lymphocytes from healthy donors and patients with depression or schizophrenia. Peptides, 2001, 22, 67-72.	2.4	23
313	Heart disease and vascular risk factors in the cognitively impaired elderly: Implications for Alzheimer's dementia. Aging Clinical and Experimental Research, 2001, 13, 231-239.	2.9	28
314	1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. NeuroReport, 2001, 12, 2315-2317.	1.2	131
315	Plasma Vitamin C Levels Are Decreased and Correlated With Brain Damage in Patients With Intracranial Hemorrhage or Head Trauma. Stroke, 2001, 32, 898-902.	2.0	88
316	Dementia, depression and parkinsonism: A frequent association in the elderly. Journal of Alzheimer's Disease, 2001, 3, 553-562.	2.6	8
317	Superficial Siderosis of the Central Nervous System: A 70-Year-Old Man with Ataxia, Depression and Visual Deficits. Gerontology, 2001, 47, 93-95.	2.8	6
318	Hyperhomocysteinemia and Oxidative Stress in Ischemic Stroke. Stroke, 2001, 32, 275-278.	2.0	4
319	The brain of the elderly between normality and pathology: Techniques and technologies for the evaluation. Archives of Gerontology and Geriatrics, 2001, 33, 77-80.	3.0	0
320	High Vitamin E Plasma Levels and Low Low-Density Lipoprotein Oxidation Are Associated with the Absence of Atherosclerosis in Octogenarians. Journal of the American Geriatrics Society, 2001, 49, 651-654.	2.6	23
321	Peripheral non-enzymatic antioxidant changes with human aging: a selective status report. Biogerontology, 2001, 2, 99-104.	3.9	13
322	Age and sex influence on oxidative damage and functional status in human skeletal muscle. Journal of Muscle Research and Cell Motility, 2001, 22, 345-351.	2.0	136
323	Plasma levels of lipophilic antioxidants in very old patients with Type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2000, 16, 15-19.	4.0	97
324	Plasma antioxidants and longevity: a study on healthy centenarians. Free Radical Biology and Medicine, 2000, 28, 1243-1248.	2.9	256

#	Article	IF	CITATIONS
325	Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radical Biology and Medicine, 2000, 29, 1252-1259.	2.9	141
326	Physical Activity and Oxidative Stress During Aging. International Journal of Sports Medicine, 2000, 21, 154-157.	1.7	76
327	Antioxidant Profile and Early Outcome in Stroke Patients. Stroke, 2000, 31, 2295-2300.	2.0	203
328	Impact of the earthquake of September 26, 1997 in Umbria, Italy on the socioenvironmental and psychophysical conditions of an elderly population. Aging Clinical and Experimental Research, 2000, 12, 281-286.	2.9	7
329	Mitochondrial DNA 4977 bp deletion and OH 8 dG levels correlate in the brain of aged subjects but not Alzheimer's disease patients. FASEB Journal, 1999, 13, 1083-1088.	0.5	74
330	Age-dependent increases in oxidative damage to DNA, lipids, and proteins in human skeletal muscle. Free Radical Biology and Medicine, 1999, 26, 303-308.	2.9	393
331	Neuropsychological assessment of the severely impaired elderly patient: Validation of the Italian short version of the Severe Impairment Battery (SIB). Aging Clinical and Experimental Research, 1999, 11, 221-226.	2.9	10
332	Area-Specific Differences in OH8dG and mtDNA4977 Levels in Alzheimer Disease Patients and Aged Controls. Rejuvenation Research, 1999, 2, 209-216.	0.2	9
333	Immunohistochemical detection of the lipid peroxidation product 4-hydroxynonenal after experimental brain injury in the rat. Neuroscience Letters, 1999, 272, 57-61.	2.1	29
334	Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neuroscience Letters, 1999, 272, 53-56.	2.1	192
335	Association of the Estrogen Receptor α Gene Polymorphisms with Sporadic Alzheimer's Disease. Biochemical and Biophysical Research Communications, 1999, 265, 335-338.	2.1	122
336	PLASMA LIPID PEROXIDATION AND VITAMIN C STATUS IN HEALTHY CENTENARIANS. Journal of the American Geriatrics Society, 1999, 47, 1038-1039.	2.6	9
337	Low Levels of 4977 BP-deleted Molecules of Mitochondrial DNA in the Presence of High OH8DG Contents in Healthy Subjects and Alzheimer's Disease Patients. Annals of the New York Academy of Sciences, 1998, 854, 494-494.	3.8	2
338	Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radical Biology and Medicine, 1998, 25, 561-567.	2.9	95
339	Oxidative stress and lymphocytes in Alzheimer disease. Archives of Gerontology and Geriatrics, 1998, 26, 313-316.	3.0	3
340	Physical activity and cardiovascular health in the elderly. Aging Clinical and Experimental Research, 1998, 10, 13-25.	2.9	9
341	Oxidative damage to DNA in lymphocytes from AD patients. Neurology, 1998, 51, 1014-1017.	1.1	165
342	Tau Protein in Cerebrospinal Fluid. Alzheimer Disease and Associated Disorders, 1998, 12, 211-214.	1.3	74

#	Article	IF	Citations
343	The Effects of Aging and Endurance Exercise on Cardiovascular Performance in Healthy Elderly: A Review of the Literature. The American Journal of Geriatric Cardiology, 1998, 7, 25-32.	0.6	3
344	AUTOANTIBODIES AGAINST OXIDIZED LOWâ€DENSITY LIPOPROTEINS IN OLDER STROKE PATIENTS. Journal of the American Geriatrics Society, 1997, 45, 125-125.	2.6	15
345	INCREASED OXIDATIVE DAMAGE IN LYMPHOCYTES OF ALZHEIMER'S DISEASE PATIENTS. Journal of the American Geriatrics Society, 1997, 45, 1536-1537.	2.6	8
346	Oxidative stress and dementia: new perspectives in AD pathogenesis. Aging Clinical and Experimental Research, 1997, 9, 51-52.	2.9	11
347	Cognitive Enhancement Therapy for Alzheimer's Disease. Drugs, 1997, 53, 752-768.	10.9	99
348	Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Molecular and Chemical Neuropathology, 1997, 31, 53-64.	1.0	200
349	Altered mitochondrial membrane fluidity in AD brain. Neuroscience Letters, 1996, 207, 129-132.	2.1	57
350	Clinical physiology-pharmacology: Age-disease-drug-related hypernatremia and hyperphosphatemia. Geriatric Nephrology and Urology, 1995, 5, 177-179.	0.3	0
351	Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. Journal of Neuroscience, 1995, 15, 8419-8429.	3.6	280
352	Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. Journal of Neuroimmunology, 1995, 57, 165-170.	2.3	62
353	Pathogenetic mechanisms in vascular dementia. International Journal of Clinical and Laboratory Research, 1994, 24, 15-22.	1.0	16
354	Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Annals of Neurology, 1994, 36, 747-751.	5.3	992
355	Oxidative damage to mitochondrial DNA shows marked ageâ€dependent increases in human brain. Annals of Neurology, 1993, 34, 609-616.	5.3	713
356	Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia. Biological Psychiatry, 1993, 34, 380-385.	1.3	23
357	Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias. Brain, Behavior, and Immunity, 1992, 6, 286-292.	4.1	17
358	Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. European Journal of Clinical Pharmacology, 1992, 42, 89-93.	1.9	72
359	Platelet MAO-B activity and vitamin B12 in old age dementias. Molecular and Chemical Neuropathology, 1992, 16, 23-32.	1.0	14
360	CSF monoamine metabolites in old age dementias. Molecular and Chemical Neuropathology, 1992, 16, 143-157.	1.0	14

#	Article	IF	CITATIONS
361	Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias. Acta Neurologica Scandinavica, 1991, 84, 210-213.	2.1	68
362	Effect of Acetyl- <i>L</i> -Carnitine on Serum Levels of Cortisol and Adrenocorticotropic Hormone and Its Clinical Effect in Patients with Senile Dementia of Alzheimer Type. Dementia and Geriatric Cognitive Disorders, 1990, 1, 165-168.	1.5	3
363	Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type. European Journal of Drug Metabolism and Pharmacokinetics, 1990, 15, 75-78.	1.6	9
364	Neuroendocrine markers in aging brain: Clinical and neurobiological significance of dexamethasone suppression test. Aging Clinical and Experimental Research, 1990, 2, 173-179.	2.9	6
365	Is multi-infarct dementia representative of vascular dementias? A retrospective study. Acta Neurologica Scandinavica, 1990, 81, 484-487.	2.1	17
366	Blood pressure and functional aspects of the aging brain. Archives of Gerontology and Geriatrics, 1989, 9, 155-161.	3.0	2
367	Neuropsychological Results of Long-Term Therapy with Oxiracetam in Patients with Dementia of Alzheimer Type and Multi-Infarct Dementia in Comparison with a Control Group. Neuropsychobiology, 1989, 22, 97-100.	1.9	10
368	Plasma Antioxidants and Oxidative DNA Damage in Lymphocytes from Normal Aged People and Alzheimer's Disease Patients., 0,, 363-369.		0